Compare ERAS & MYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.